Having successfully shepherded the company he founded through clinical trials, raising $100 million and finally winning regulatory clearance, InfraReDx CEO Dr. James Muller is leaving the corner office for a seat as chairman of the board.
InfraReDx Inc.
MassDevice Podcast: InfraReDx CEO Dr. James Muller
InfraReDx Inc. is on a roll this fall. The Burlington, Mass.-based medical device maker won 510(k) clearance from the Food & Drug Administration in early September for its LipiScan IVUS coronary imaging system and pulled in $21 million in an equity offering a month later, which it plans to use to fund the U.S. rollout of the device.
The LipiScan IVUS uses both so-called “near-infrared” spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.
InfraReDx pulls in $21 million for U.S launch of arterial plaque detector
InfraReDx Inc. drummed up $21 million in an equity offering, aiming to get its arterial plaque imaging system to market in the U.S.
The Burlington, Mass.-based company makes the LipiScan IVUS coronary imaging system, which combines intravascular ultrasound and near-infrared spectroscopy to detect lipid core plaque in the heart’s blood vessels. The data enables cardiologists to both visualize coronary plaques to guide stent placement and determine whether the build-ups are comprised of the fatty plaques that complicate stenting procedures and patients’ recovery .
InfraReDx wins FDA clearance for coronary imaging system
The Food & Drug Administration gave InfraReDx Inc. 510(k) clearance for the company’s LipiScan IVUS coronary imaging system.
The device employs both so-called "near-infrared" spectroscopy and intravascular ultrasound technology to give cardiologists a grayscale IVUS image of a coronary artery, along with a map of lipid core coronary plaques within a blood vessel.
InfraReDx rings up $10 million more in convertible debt sale
InfraReDx Inc. raised an additional $10 million through the sale of convertible promissory notes, according to a filing with the Securities and Exchange Commission, taking the Burlington, Mass.-based company’s total fundraising effort to nearly $100 million after more than a decade of operation.
A spokesman for the company told MassDevice that the firm wouldn’t be making any comment on the new round until CEO James Muller returned from presenting at the JP Morgan Healthcare Investors Conference in San Francisco this week.